AbbVie Inc. (ABBV)
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
4 Big Drug Stocks That May Continue to Outperform in 2025
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. The post AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth.
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.
Why Investors Should Watch AbbVie Inc (ABBV)
AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines. AbbVie focuses primarily on immunology, oncology, neuroscience, and virology treatments, and it has a broad portfolio of prescription drugs aimed at addressing a range of medical conditions.
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors
AbbVie offers a compelling investment opportunity after a recent price drop, combining dividend income, value, and growth potential driven by a strong drug portfolio and pipeline. Robust growth in immunology with Skyrizi and Rinvoq, resilience in oncology and aesthetics, and expanded Botox indications support long-term prospects. A solid balance sheet, manageable debt, and a 3.8% yield with consistent dividend growth make AbbVie attractive for diversified pharmaceutical exposure.
AbbVie Enters Oversold Territory
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Investing in a company to hold it forever is a simple idea, but it's not easy. Most companies can't maintain competitive advantages forever.
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times.
